Omnicell (NASDAQ:OMCL) Stock Rating Raised to “Strong-Buy” at Zacks Research

Zacks Research upgraded shares of Omnicell (NASDAQ:OMCL) from a hold rating to a strong-buy rating in a research note issued to investors on Wednesday,Zacks reports.

Other analysts have also recently issued research reports about the stock. Wells Fargo & Company cut their price target on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Piper Sandler reiterated an “overweight” rating and set a $45.00 price target (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. KeyCorp reissued an “overweight” rating on shares of Omnicell in a research report on Monday, August 24th. Finally, Weiss Ratings raised Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $57.86.

Omnicell Stock Performance

NASDAQ:OMCL opened at $38.03 on Wednesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.45 and a current ratio of 1.65. Omnicell has a fifty-two week low of $31.75 and a fifty-two week high of $55.00. The company has a 50 day simple moving average of $34.85 and a two-hundred day simple moving average of $38.84. The company has a market capitalization of $1.73 billion, a PE ratio of 39.61, a P/E/G ratio of 0.98 and a beta of 0.88.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, October 29th. The company reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.16. Omnicell had a net margin of 3.59% and a return on equity of 5.69%. The firm had revenue of $307.85 million for the quarter, compared to the consensus estimate of $304.44 million. During the same quarter in the previous year, the company earned $0.51 EPS. The company’s revenue for the quarter was down .9% on a year-over-year basis. Research analysts anticipate that Omnicell will post 1.64 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of OMCL. Nykredit A S acquired a new position in shares of Omnicell during the second quarter worth approximately $26,000. Versant Capital Management Inc lifted its holdings in shares of Omnicell by 38.7% in the 2nd quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock worth $44,000 after purchasing an additional 294 shares in the last quarter. Fulcrum Asset Management LLP lifted its holdings in shares of Omnicell by 2,536.4% in the 3rd quarter. Fulcrum Asset Management LLP now owns 1,160 shares of the company’s stock worth $40,000 after purchasing an additional 1,116 shares in the last quarter. Northwestern Mutual Wealth Management Co. acquired a new stake in Omnicell in the 2nd quarter valued at $105,000. Finally, Nisa Investment Advisors LLC grew its position in Omnicell by 21.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,613 shares of the company’s stock valued at $89,000 after purchasing an additional 469 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Key Omnicell News

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Zacks said solid upward earnings-estimate revisions could support further near-term gains, and added OMCL to its Rank #1 (Strong Buy) lists for November 5, including its momentum and value selections. Why Omnicell Might be Well Poised for a Surge New Strong Buy Stocks
• Positive Sentiment: Analyst price targets imply substantial potential upside, with one report citing a consensus target of $57.86 and another estimating 40.8%. The article cautions that price targets alone have limited predictive value; estimate revisions may be a more meaningful near-term signal. Omnicell Consensus Target Price Omnicell Potential Rally
• Neutral Sentiment: Omnicell was included in a roundup of robotics stocks with long-term growth potential, but the article offered no new company-specific catalyst. Top Robotics Stocks
• Negative Sentiment: The recent earnings backdrop is mixed: Omnicell beat quarterly EPS and revenue estimates, but revenue was down 0.9% year over year. That modest decline may temper optimism around the positive estimate-revision signals.

Omnicell Company Profile

Omnicell, Inc develops medication management and adherence solutions for health care providers, pharmacies and patients. Its technologies are designed to help automate medication dispensing, improve inventory control, support clinical workflows and enhance medication access and adherence across the care continuum.

The company’s product portfolio includes automated dispensing cabinets for hospitals and health systems, central pharmacy and intravenous compounding automation, medication packaging and adherence solutions, and software for analytics, inventory management and pharmacy operations.